Celsion   Report issue

For profit Phase 2 Phase 3
Founded: Lawrenceville NJ United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2001
NCT00036985
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Celsion | Celsus Therapeutics PLC

Active Ingredients

Drugs in Phase 3 Trials (2)

doxorubicin (Doxil) (10 trials)

glucose monohydrate (2 trials)

Drugs in Phase 2 Trials (6)

Key: Celsion (5) Acquired (1)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

egen-001 (3 trials)

gen-1 (2 trials)

mrx-6 (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Colonic Neoplasms (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Fever (Phase 2)

Liver Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 8